- Home
- LRMR vs SLP Comparison
LRMR vs SLP Comparison
Compare LRMR & SLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LRMR | SLP |
|---|---|---|
| Founded | N/A | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 316.6M | 322.4M |
| IPO Year | N/A | 1997 |
Fundamental Metrics
Financial Performance| Metric | LRMR | SLP |
|---|---|---|
| Price | $3.41 | $19.08 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 7 |
| Target Price | $16.71 | ★ $27.25 |
| AVG Volume (30 Days) | ★ 1.1M | 251.6K |
| Earning Date | 11-05-2025 | 01-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $79,179,000.00 |
| Revenue This Year | N/A | $2.42 |
| Revenue Next Year | N/A | $7.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 13.09 |
| 52 Week Low | $1.61 | $12.39 |
| 52 Week High | $5.37 | $37.67 |
Technical Indicators
Market Signals| Indicator | LRMR | SLP |
|---|---|---|
| Relative Strength Index (RSI) | 41.31 | 55.19 |
| Support Level | $3.31 | $17.73 |
| Resistance Level | $4.01 | $19.78 |
| Average True Range (ATR) | 0.24 | 0.73 |
| MACD | -0.06 | -0.05 |
| Stochastic Oscillator | 14.34 | 65.61 |
Price Performance
Historical ComparisonAbout LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
About SLP Simulations Plus Inc.
Simulations Plus Inc is engaged in the software industry. It includes two segments. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.